Try our Advanced Search for more refined results
Life Sciences
-
April 06, 2026
Judge Won't Alter $631K SEC Penalty Against Atty
A Connecticut attorney found liable for violating securities laws as a part of an alleged sham merger agreement can't get his $631,000 penalty modified after a Boston federal judge rejected the attorney's argument that the penalty sum reflects an unjust "double-count[ing]" error.
-
April 06, 2026
Ayahuasca Church Urges Judge To Halt DEA Enforcement
A Florida church that has used a federally prohibited psychedelic as part of its rites is asking a federal court to block raids on it after filing suit against the government in February over claims that law enforcement ransacked its Orlando-area sanctuary and detained its members in violation of the Religious Freedom Restoration Act.
-
April 06, 2026
Biz Groups Urge 4th Circ. To End Allergan Overcharge Suit
Major pharmaceutical and business associations urged the Fourth Circuit to reconsider a panel decision that revived a whistleblower lawsuit accusing an Allergan Sales LLC predecessor of overcharging Medicaid, warning it threatens to become a road map for False Claims Act abuses.
-
April 06, 2026
Bausch, MSN Laboratories Settle Patent Battle Over IBS Drug
Bausch Health and MSN Laboratories have ended their New Jersey patent fight over the irritable bowel medication Trulance after reaching a confidential settlement, filing a stipulation of dismissal that lets MSN keep its patent challenge and lifts the 30‑month stay blocking FDA approval of its proposed generic drug.
-
April 06, 2026
Splenda Loses Bid To End Scientist's Libel Counterclaim
The maker of Splenda lost its bid for a pretrial win on a scientist's counterclaims for libel after a North Carolina federal judge on Monday ruled they weren't filed too late because the counterclaims are directly linked to the company's defamation suit challenging her statements linking Splenda to cancer-causing chemicals.
-
April 06, 2026
Judge Slashes Damages For Natera In Invitae Patent Case
A Delaware federal judge knocked nearly $10 million off a $19.35 million damages award for Natera Inc. on Monday, but added supplemental damages and interest to a patent infringement verdict against Invitae Corp. related to cancer testing technology.
-
April 06, 2026
Settlement In Sight For Amway, Supplement Co. In TM Dispute
A trademark dispute over gut health products between a supplement-maker and multi-level marketing giant Amway Corp. may be headed for settlement, according to a motion from Begin Health Inc. asking a North Carolina federal court to delay a coming hearing.
-
April 06, 2026
Pfizer Failed To Warn Of Depo-Provera Cancer Risk, Suit Says
A Georgia woman who alleged she developed a brain tumor after taking the contraceptive drug Depo-Provera sued Pfizer in federal court, claiming the company failed to warn American patients about the danger even though it does so on warning labels in the European Union.
-
April 06, 2026
WilmerHale Adds Regulatory Atty From Mayer Brown In DC
WilmerHale announced Monday it has hired a veteran U.S. Food and Drug Administration and life sciences regulatory attorney from Mayer Brown LLP.
-
April 06, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court's docket this past week featured a mix of high-profile corporate disputes, insider trading allegations, contract fights and significant rulings shaping fiduciary duty and deal litigation.
-
April 06, 2026
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy
Neurocrine Biosciences has agreed to acquire biotechnology company Soleno Therapeutics for about $2.9 billion in cash, in a deal advised by Cooley LLP and Wilson Sonsini Goodrich & Rosati PC, the companies said on Monday.
-
April 03, 2026
Case-By-Case Guide As Justices Eye Landmark Pharma Law
Drugmakers and prominent allies are inundating the U.S. Supreme Court with calls to scrutinize Medicare's new power to slash payments by tens of billions of dollars, and the justices look poised to take up or turn down a fistful of legal challenges in one fell swoop.
-
April 03, 2026
Barnes & Thornburg Snags PFAS Expert From Venable
Barnes & Thornburg LLP is beefing up its product liability and mass torts practice with the addition of a Venable LLP partner known for representing and counseling companies in environmental and toxic tort-related matters, including issues involving so-called forever chemicals, the firm announced Thursday.
-
April 03, 2026
SEC Moves To Set Up $40M Investor Fund In Cassava Case
The U.S. Securities and Exchange Commission asked a Texas federal court on Friday to establish a $40 million fund to potentially compensate investors harmed by a Texas biopharmaceutical company and two former executives' alleged misstatements about an Alzheimer's drug, following the company's 2024 settlement with the regulator.
-
April 03, 2026
Legislative Update: Cannabis And Psychedelics Bill Roundup
State lawmakers in Delaware and West Virginia advanced legislation to more tightly regulate kratom products, Missouri and Kentucky legislators considered bills to fund research into the therapeutic uses of the psychedelic ibogaine, and Idaho's Legislature came together to urge voters to reject a medical marijuana legalization proposal that could be on the ballot this November. Here are the major moves in cannabis and psychedelics legislation from the past week.
-
April 03, 2026
EPA Eyes Microplastics, Drugs For Drinking Water Watch List
The U.S. Environmental Protection Agency is looking to include microplastics and pharmaceuticals in its drinking water contaminants list for the first time, the agency has announced in a move it says could make the proposed contaminants a consideration in regulatory action.
-
April 03, 2026
Law360 Announces The Members Of Its 2026 Editorial Boards
Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.
-
April 03, 2026
Aetna Escapes COVID Testing Payment Suit In Calif.
A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit.
-
April 03, 2026
NYC Fights Sanctions Over Discovery In IVF Sex Bias Dispute
New York City urged a federal judge to reject a gay couple's sanctions bid in their suit claiming a municipal health plan blocked them from receiving in vitro fertilization coverage out of discrimination, calling their concerns with the city's sluggish discovery production in the case premature.
-
April 03, 2026
Caterpillar Worker's Bankruptcy Dooms Genetic Privacy Claim
An Illinois federal judge has thrown out a Caterpillar Inc. employee's proposed class genetic privacy suit over allegedly illegal medical history probes, saying the worker's midcase Chapter 7 bankruptcy filing means the claims now belong to his bankruptcy estate and not to him personally.
-
April 02, 2026
Georgia Midwifery Laws Violate State Constitution, Suit Says
A trio of midwives are challenging Georgia laws that restrict their ability to practice, arguing that the statutes exacerbate an ongoing maternal health crisis and conflict with the Peach State's constitution.
-
April 02, 2026
Squires Gives Go-Ahead To 5 Patent Reviews, Denies 8
In the latest order summarizing his decisions on requests for America Invents Act patent reviews, U.S. Patent and Trademark Office Director John Squires has granted five petitions and turned down eight others.
-
April 02, 2026
Petition To Repeal Legal Pot Mobilizes A Showdown In Mass.
A campaign to repeal the legalization of retail cannabis in Massachusetts via ballot initiative — the first campaign of its kind in the country — is uniting legalization advocates, entrepreneurs and industry players in a coordinated response to defeat the effort before it spreads to other states.
-
April 02, 2026
Ex-Pharma Exec Hit With $5.3M Fee Award In Del.
The Delaware Chancery Court has ordered a former pharmaceutical executive to pay more than $5.3 million in attorney fees following years of litigation over alleged disloyal conduct and trade secret misuse, concluding that the award is reasonable despite objections that the amount was excessive.
-
April 02, 2026
Alexion Beats Trade Secret Claims In Amyndas Suit
Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.
Expert Analysis
-
Series
Playing Piano Makes Me A Better Lawyer
Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.
-
3 Cases Highlight SEC Distinction Between Exec, Co. Liability
Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.
-
AI-Generated Doc Ruling Guides Attys On Privilege Risks
A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.
-
The Law Firm Merger Diaries: Leadership Strategy After Day 1
For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.
-
Record FCA Recoveries Signal Intensified Healthcare Focus
In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.
-
Fed. Circ. In Jan.: On The Validity Of Expert Testimony
The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.
-
Calif.'s Civility Push Shows Why Professionalism Is Vital
The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.
-
A Potential Shift In FDA's Approach To Drug Trial Design
Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.
-
Series
Trivia Competition Makes Me A Better Lawyer
Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.
-
What FDA Guidance Means For Future Of Health Software
Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.
-
Opinion
Federal Preemption In AI And Robotics Is Essential
Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.
-
Series
Law School's Missed Lessons: What Cross-Selling Truly Takes
Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.
-
Drafting Tech Patents After USPTO's Eligibility Memos
Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.
-
How State FCA Activity May Affect Civil Fraud Enforcement
A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.
-
Series
Judges On AI: Practical Use Cases In Chambers
U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.